Carboplatin and paclitaxel are to be given only after veliparib/placebo dosing on Day –2 and Day –1 are confirmed.

Table 1. Treatment Schema for Each Cycle

			Week 1				
Days	**–2**	**–1**	**1**	**2**	**3**	**4**	**5**
Veliparib/Placebo	Twice a day	Twice a day	Twice a day	Twice a day	Twice a day	Twice a day	Twice a day
Paclitaxel			Once				
Carboplatin			Once				
			Week 2				
	6	**7**	**8**	**9**	**10**	**11**	**12**
Veliparib/Placebo							
Paclitaxel			Once				
Carboplatin							
			Week 3				
	13	**14**	**15**	**16**	**17**	**18**	**19**
Veliparib/Placebo							
Paclitaxel			Once				
Carboplatin							

Subjects will continue to receive veliparib/placebo in combination with carboplatin/paclitaxel until unacceptable toxicity occurs or radiographic progression occurs. Subjects who experience toxicities due to carboplatin/paclitaxel or veliparib may require a delay in dosing or dose modification as described in Section 5.7.

Subjects who discontinue carboplatin and paclitaxel due to toxicity and who have not progressed are eligible to receive single-agent, blinded veliparib/placebo starting at 300 mg BID. If the subject tolerates 300 mg BID for 2 weeks, veliparib/placebo may be increased to 400 mg BID at the investigator's discretion. Dosing with veliparib/placebo will begin on Day -2 and continue through Day 19 of a 21-day cycle. Subjects will continue to follow the schedule of assessments as outlined in Table 2.